Recent Company News

• 08:03 AM ET Jan 23, 2026
  

  Adagene reports year-end cash and equivalents of $74.5M, outlines 2026 objectives ($2.03, 0.00)

• 09:16 AM ET Dec 16, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:28 AM ET Dec 16, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:06 AM ET Dec 16, 2025
  

  Adagene announces FDA fast track designation for Muzastotug (ADG126) ($1.67, 0.00)

• 06:09 AM ET Nov 24, 2025
  

  Adagene initiated buy at Guggenheim Securities ($1.80, 0.00)

• 02:47 PM ET Nov 17, 2025
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 10-Nov

• 06:02 AM ET Nov 14, 2025
  

  Adagene initiated outperform at LifeSci Capital ($1.80, 0.00)

• 07:09 AM ET Nov 13, 2025
  

  Adagene announces licensing agreement with Third Arc Bio for development of two masked CD3 T cell engagers utilizing SAFEbody technology ($1.77, 0.00)

• 07:04 AM ET Oct 31, 2025
  

  Adagene announces first patient dosed in randomized dose optimization cohort of the phase 2 study of muzastotug (ADG126) in combination with KEYTRUDA in microsatellite stable colorectal cancer ($1.92, 0.00)

• 04:39 PM ET Sep 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market